Lilly Forteo launch
Executive Summary
Lilly expects to launch the osteoporosis drug Forteo "at the end of this year or early next year, depending on the timing of...approval in the fourth quarter," Exec VP August Watanabe tells analysts at Banc of America Securities Conference Sept. 10. In July, FDA's Endocrinologic & Metabolic Drugs Advisory Committee recommended the drug for the treatment of osteoporosis in postmenopausal women but said the indication should be restricted to high-risk patients and second-line use (1"The Pink Sheet" July 30, p. 3)